Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform.

The blood-brain barrier (BBB) serves as a protective barrier for the central nervous system (CNS) against drugs that enter the bloodstream. The BBB is a key clinical barrier in the treatment of CNS illnesses because it restricts drug entry into the brain. To bypass this barrier and release relevant drugs into the brain matrix, nanotechnology-based delivery systems have been developed. Given the unstable nature of NPs, an appropriate amount of a biocompatible polymer coating on NPs is thought to have a key role in reducing cellular cytotoxicity while also boosting stability. Human serum albumin (HSA), poly (lactic-co-glycolic acid) (PLGA), Polylactide (PLA), poly (alkyl cyanoacrylate) (PACA), gelatin, and chitosan are only a few of the significant polymers mentioned. In this review article, we categorized polymer-coated nanoparticles from basic to complex drug delivery systems and discussed their application as novel drug carriers to the brain.

Recent Advances in Nanotechnology for the Management of Klebsiella pneumoniae-Related Infections.

Klebsiella pneumoniae is an important human pathogen that causes diseases such as urinary tract infections, pneumonia, bloodstream infections, bacteremia, and sepsis. The rise of multidrug-resistant strains has severely limited the available treatments for K. pneumoniae infections. On the other hand, K. pneumoniae activity (and related infections) urgently requires improved management strategies. A growing number of medical applications are using nanotechnology, which uses materials with atomic or molecular dimensions, to diagnose, eliminate, or reduce the activity of different infections. In this review, we start with the traditional treatment and detection method for K. pneumoniae and then concentrate on selected studies (2015-2022) that investigated the application of nanoparticles separately and in combination with other techniques against K. pneumoniae.

Polyacrylic Acid Nanoplatforms: Antimicrobial, Tissue Engineering, and Cancer Theranostic Applications.

Polyacrylic acid (PAA) is a non-toxic, biocompatible, and biodegradable polymer that gained lots of interest in recent years. PAA nano-derivatives can be obtained by chemical modification of carboxyl groups with superior chemical properties in comparison to unmodified PAA. For example, nano-particles produced from PAA derivatives can be used to deliver drugs due to their stability and biocompatibility. PAA and its nanoconjugates could also be regarded as stimuli-responsive platforms that make them ideal for drug delivery and antimicrobial applications. These properties make PAA a good candidate for conventional and novel drug carrier systems. Here, we started with synthesis approaches, structure characteristics, and other architectures of PAA nanoplatforms. Then, different conjugations of PAA/nanostructures and their potential in various fields of nanomedicine such as antimicrobial, anticancer, imaging, biosensor, and tissue engineering were discussed. Finally, biocompatibility and challenges of PAA nanoplatforms were highlighted. This review will provide fundamental knowledge and current information connected to the PAA nanoplatforms and their applications in biological fields for a broad audience of researchers, engineers, and newcomers. In this light, PAA nanoplatforms could have great potential for the research and development of new nano vaccines and nano drugs in the future.

Development of a multifunctional system based on CoFe2O4@polyacrylic acid NPs conjugated to folic acid and loaded with doxorubicin for cancer theranostics.

In this work, a multifunctional theranostic nanocomposite based on CoFe2O4@polyacrylic acid (PAA)-Folic Acid (FA) Doxorubicin (Dox)loadNPs was designed for the multifunctional cancer treatment. Several techniques such as TEM, DLS,ζ-potential, vibrating sample magnetometer, XRD, and UV-Vis spectrophotometer were applied for investigating physicochemical properties of the nanosystem. The percentage of the loaded drug, loading efficiency,in vitrorelease (pH 5.4 and 7.4),invitroMRI measurements, and MTT assay (4T1 and 9A9 cell lines) were evaluated. Results showed that the percentage of loaded drug and loading efficiency was 53.33 ± 3.5 and 80.00 ± 5.3%, respectively, showing the system's high ability for Dox encapsulation. Release study showed that Dox loaded in the CoFe2O4@PAA-FA(Dox)loadNPs released faster at pH 5.4 than pH 7.4.In vitro, MRI measurements confirmed that CoFe2O4@PAA NPs could be used as a contrast agent in MRI measurements withr2 = 18.2 mM-1s-1. MTT assay demonstrated the biocompatibility of NPs, also showed a more efficient therapeutic effect for CoFe2O4@PAA-FA(Dox)loadNPs than free Dox and CoFe2O4@PAA(Dox)loadNPs.

A drug delivery system based on nanocomposites constructed from metal-organic frameworks and Mn3O4 nanoparticles: Preparation and physicochemical characterization for BT-474 and MCF-7 cancer cells.

An integrated nanocomposite system comprising of manganese oxide (Mn3O4) nanoparticles, functioning as a tumor diagnostic agent, in conjunction with polyacrylic acid (PAA) and ZIF-8, as pH-sensitive drug delivery agents, and methotrexate (MTX), operating as a tumor biomarker and a therapeutic agent (dual mechanism of action), is applied for both diagnostic intentions and controlled delivery of the drug. Physicochemical characteristics of the constructed system, Mn3O4@PAA@ZIF-8/MTX, are investigated by several methods, including X-ray diffraction, Fourier transform infrared spectroscopy, field-emission scanning electron microscopy, and electrochemical techniques. The in-vitro magnetic resonance imaging measurements was performed to show the efficiency of Mn3O4@PAA@ZIF-8 nanocomposite as a contrast agent where a relaxivity (r1) of 3.3 mM-1 s-1 is found. The loading ratio was found as 161 % which is four times larger than the value obtained for Mn3O4@PAA system in the same conditions, indicating high capability of the system for MTX delivery. The application of the nanocomposite as a dual pH-sensitive nanocarrier for MTX is studied through in-vitro drug release experiments at pHs of 5.4, 6.8 and 7.4. Interestingly, the results show that a large amount of loaded MTX drug (53 %) is released from the system during incubation and dialysis at pH 5.4, compared with that (20 % and 15 %), respectively, released at pHs 6.8 and 7.4 at the same conditions. The affinity of Mn3O4@PAA@ZIF-8/MTX nanocomposite for capturing of BT-474 and MCF-7 cancer cells was evaluated via impedance spectroscopy measurements. The results show that GC-Mn3O4@PAA@ZIF-8/MTX electrode captures the BT-474 and MCF-7 cancer cells, respectively, by factors of ∼2 and 196 compared with L929 normal cells. This affinity also shows the high selectivity of the system for MCF-7 cancer cells compared with BT-474.